Knudsen J F, Friedman B, Chen M, Goldwasser J E
Division of Neuropharmacologic Drug Products, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD 20857, USA.
Arch Intern Med. 1998 Sep 28;158(17):1946-8. doi: 10.1001/archinte.158.17.1946.
Sumatriptan succinate, a serotonin-1 (5-hydroxytryptamine-1) receptor agonist, is an antimigraine drug that is reported to act by selectively constricting intracranial arteries. Recently, vasopressor responses that are distinct from the cranial circulation have been demonstrated to occur in the systemic, pulmonary, and coronary circulations. Cases have been published of coronary vasospasm, myocardial ischemia, and myocardial infarction occurring after sumatriptan use. We report on the development of 8 serious cases of ischemic colitis in patients with migraine treated with sumatriptan.
琥珀酸舒马曲坦是一种5-羟色胺-1（5-羟色胺-1）受体激动剂，是一种抗偏头痛药物，据报道其作用机制是选择性收缩颅内动脉。最近，已证实在体循环、肺循环和冠状动脉循环中会出现与颅循环不同的升压反应。已有使用舒马曲坦后发生冠状动脉痉挛、心肌缺血和心肌梗死的病例报道。我们报告了8例使用舒马曲坦治疗偏头痛患者发生严重缺血性结肠炎的情况。
